The SGLT2 inhibitors are new oral anti-diabetic agents that promote renal glucose excretion in an insulin-independent mechanism, being well established in the treatment of T2DM (Frampton, 2018). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.